Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disability Evaluation Clear all
Completed No phase listed Observational

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718910
View directory record Official record
Conditions
DDX3X, Mental Retardation, X-linked 102, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

NCT00570128
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional

Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children

NCT02359084
View directory record Official record
Conditions
Autism, Developmental Delay Disorders
Interventions
Family Navigation, Conventional Care Management
Behavioral
Lead sponsor
Boston University
Other
Eligibility
15 Months to 27 Months
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
New Haven, Connecticut • Boston, Massachusetts • Chelsea, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

NCT00788073
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
STX209, Placebo
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
6 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Jul 22, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Assessment and Treatment of Problem Behavior in Children With Cornelia de Lange Syndrome

NCT05829668
View directory record Official record
Conditions
Cornelia de Lange Syndrome
Interventions
ABA-based functional analysis and treatment
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
3 Years to 15 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 22, 2026, 5:13 AM EDT
Withdrawn Phase 3 Interventional

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

NCT01221740
View directory record Official record
Conditions
Back Pain
Interventions
Savella
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 5:13 AM EDT
Terminated Not applicable Interventional Results available

Pneumatic Technology for Powered Mobility Devices

NCT03898362
View directory record Official record
Conditions
Disability
Interventions
pneumatically powered wheelchair or scooter, battery powered wheelchair or scooter
Other · Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 22, 2026, 5:13 AM EDT
Completed No phase listed Observational

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

NCT01555346
View directory record Official record
Conditions
Down Syndrome, Fetal Aneuploidy
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Mobile, Alabama • Tucson, Arizona • Campbell, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Assessment of e-Audiology for Providing Clinical Services and Support

NCT04048460
View directory record Official record
Conditions
Hearing Loss, Age-Related, Presbycusis, Bilateral, Hearing Disability
Interventions
Delivery of hearing healthcare through eAudiology application
Device
Lead sponsor
University of South Florida
Other
Eligibility
70 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Jul 22, 2026, 5:13 AM EDT
Completed No phase listed Observational

Evaluation of Patients With Unresolved Chromosome Abnormalities

NCT00001639
View directory record Official record
Conditions
Abnormalities, Failure to Thrive, Mental Retardation, Microcephaly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

NCT05153434
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
17 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 22, 2026, 5:13 AM EDT
Recruiting No phase listed Observational

FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718923
View directory record Official record
Conditions
FOXP1, Mental Retardation With Language Impairment and With or Without Autistic Features, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 5:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children's Autism Metabolome Project

NCT02548442
View directory record Official record
Conditions
Autism Spectrum Disorder, Developmental Disorder
Interventions
Not listed
Lead sponsor
Stemina Biomarker Discovery, Inc.
Industry
Eligibility
18 Months to 48 Months
Enrollment
1,102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
8
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional

Investigating Trunk Control in Young Children With Down Syndrome

NCT03544840
View directory record Official record
Conditions
Down Syndrome, Gross Motor Development Delay
Interventions
Physical Therapy Home Program
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
6 Months to 24 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Jul 22, 2026, 5:13 AM EDT
Not listed Not applicable Interventional

RETAIN Kentucky Impact Evaluation

NCT05173350
View directory record Official record
Conditions
Disability
Interventions
RETAIN KY, Active Comparator
Other
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment

NCT00699660
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
CAPS/WHODAS, Nonstructured Interview
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
North Little Rock, Arkansas • Palo Alto, California • West Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jul 22, 2026, 5:13 AM EDT
Completed No phase listed Observational

Neonatal Seizure Registry - Developmental Functional EValuation

NCT04337697
View directory record Official record
Conditions
Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhages, Epilepsy, Cerebral Palsy, Intellectual Disability
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 8 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis

NCT01124292
View directory record Official record
Conditions
Quadriplegia, Spinal Cord Injury, ALS
Interventions
Tongue Piercing, Usability assessment
Procedure · Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jul 22, 2026, 5:13 AM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444
View directory record Official record
Conditions
Rett Syndrome
Interventions
fenfluramine hydrochloride, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
5 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Little Rock, Arkansas • Orlando, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

NCT01357239
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Sacramento, California • Decatur, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 22, 2026, 5:13 AM EDT
Recruiting Phase 3 Interventional

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT07480564
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
2 Years to 3 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

NCT00251303
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder, Developmental Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Jul 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional

Ohio RETAIN Impact Evaluation

NCT05219045
View directory record Official record
Conditions
Disability
Interventions
Ohio RETAIN
Other
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
4,525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PEAKS: Validation of Mobile Technologies

NCT02888483
View directory record Official record
Conditions
Health Services for Persons With Disabilities, Disability Evaluation, Exercise, Fitness Trackers, Validation Studies
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jul 22, 2026, 5:13 AM EDT